Sanofi has paid €120 million upfront and committed to up to €495 million more for a stake in AstraZeneca’s experimental monoclonal antibody against RSV.
Two months ago Novavax announced that its Phase III RSV F vaccine flopped fantastically, and now, with a sense of inevitability, it has announced a “corporate restructure.”
Novavax saw its shares plummet afterhours yesterday when it announced a late-stage test of its infectious respiratory disease vaccine missed all of its marks across the 12,000-strong study.